IGI and AstraZeneca to Collaborate on Genetic Role in Disease Pathology

The Innovative Genomics Initiative (IGI) today announced a new research collaboration with global biopharmaceutical company AstraZeneca using CRISPR genomic editing tools to address research applications across a broad range of therapeutic areas. IGI and AstraZeneca will be working closely together to identify and validate gene targets relevant to cancer; cardiovascular, metabolic, respiratory, autoimmune and inflammatory diseases; and regenerative medicine.

More information about this new collaboration will be available at the IGI Grand Opening Celebration on Feb 4, 2015.